Did Biohaven's BHV-7000 trial for MDD succeed?

The Phase II trial for major depressive disorder (MDD) did not meet its primary endpoint, but showed promising trends in severe depression subgroups.

What were the side effects of BHV-7000 in the trial?

BHV-7000 demonstrated good overall tolerability, with mostly mild or moderate adverse events like headache and nausea.

When will Biohaven present further BHV-7000 data?

Biohaven plans to share further results from the BHV-7000 trial at a forthcoming scientific conference.

Home / Health / Biohaven's Depression Drug Trial Misses Key Goal

Biohaven's Depression Drug Trial Misses Key Goal

26 Dec

•

Summary

BHV-7000 did not achieve its primary endpoint in the MDD trial.
Trends favored the drug in severe depression subgroups.
The drug demonstrated good tolerability and safety overall.

Biohaven's Depression Drug Trial Misses Key Goal

Biohaven recently announced the results from its Phase II trial for BHV-7000, a potential treatment for major depressive disorder (MDD). The study, which evaluated depressive symptom reduction over six weeks, unfortunately did not achieve its primary endpoint when compared against a placebo.

Despite missing the main objective, the trial identified encouraging trends. BHV-7000 showed promise in specific subgroups of patients who exhibited more severe depression at the start of the study, as measured by both primary and secondary assessments. The drug was generally well-tolerated, with adverse events being mild to moderate and resolving on their own.

Further analysis of the BHV-7000 data is underway, with Biohaven planning to present these findings at an upcoming scientific conference. The company also highlighted its ongoing development programs, including trials for other conditions like focal epilepsy, Graves' disease, IgA nephropathy, obesity, and Parkinson's disease.